Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
Eichhorn F, Klotz LV, Kriegsmann M, Bischoff H, Schneider MA, Muley T, Kriegsmann K, Haberkorn U, Heussel CP, Savai R, Zoernig I, Jaeger D, Thomas M, Hoffmann H, Winter H, Eichhorn ME. Eichhorn F, et al. Among authors: haberkorn u. Lung Cancer. 2021 Mar;153:150-157. doi: 10.1016/j.lungcan.2021.01.018. Epub 2021 Jan 21. Lung Cancer. 2021. PMID: 33529989 Clinical Trial.
Imaging of lung cancer with CT, MRT and PET.
Haberkorn U, Schoenberg SO. Haberkorn U, et al. Lung Cancer. 2001 Dec;34 Suppl 3:S13-23. doi: 10.1016/s0169-5002(01)00369-5. Lung Cancer. 2001. PMID: 11740988 Review.
Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518).
Jensen AD, Münter MW, Bischoff H, Haselmann R, Timke C, Krempien R, Sterzing F, Nill S, Heeger S, Hoess A, Haberkorn U, Huber PE, Steins M, Thomas M, Debus J, Herfarth KK. Jensen AD, et al. Among authors: haberkorn u. BMC Cancer. 2006 May 8;6:122. doi: 10.1186/1471-2407-6-122. BMC Cancer. 2006. PMID: 16681848 Free PMC article. Clinical Trial.
A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jäger D. Berger AK, et al. Among authors: haberkorn u. BMC Cancer. 2012 Mar 22;12:108. doi: 10.1186/1471-2407-12-108. BMC Cancer. 2012. PMID: 22439666 Free PMC article. Clinical Trial.
Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial.
Askoxylakis V, Dinkel J, Eichinger M, Stieltjes B, Sommer G, Strauss LG, Dimitrakopoulou-Strauss A, Kopp-Schneider A, Haberkorn U, Huber PE, Bischof M, Debus J, Thieke C. Askoxylakis V, et al. Among authors: haberkorn u. Radiat Oncol. 2012 Sep 14;7:157. doi: 10.1186/1748-717X-7-157. Radiat Oncol. 2012. PMID: 22974533 Free PMC article. Clinical Trial.
Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.
Sachpekidis C, Thieke C, Askoxylakis V, Nicolay NH, Huber PE, Thomas M, Dimitrakopoulou G, Debus J, Haberkorn U, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Among authors: haberkorn u. Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):127-42. eCollection 2015. Am J Nucl Med Mol Imaging. 2015. PMID: 25973334 Free PMC article.
589 results